Synthesis and Characterization of New Ruthenium Cl[sub.2]L] and Their Cytotoxicity against HeLa-Type Cancer Cells

When the [Ru(p-cymene)(μ-Cl)Cl][sub.2] complex is made to react, in dichloromethane, with the following ligands: 2-aminobenzonitrile (2abn), 4-aminobenzonitrile (4abn), 2-aminopyridine (2ampy) and 4-aminopyridine (4ampy), after addition of hexane, the following compounds are obtained: [Ru(p-cymene)C...

Full description

Saved in:
Bibliographic Details
Published inMolecules (Basel, Switzerland) Vol. 27; no. 21
Main Authors Fuster, Marta G, Moulefera, Imane, Montalbán, Mercedes G, Pérez, José, Víllora, Gloria, García, Gabriel
Format Journal Article
LanguageEnglish
Published MDPI AG 01.10.2022
Subjects
Cancer
Cervical cancer
Crystals
Drug resistance
Ethylenediaminetetraacetic acid
Ruthenium
Structure
United States
Spain
Online AccessGet full text

Cover

More Information
Summary:When the [Ru(p-cymene)(μ-Cl)Cl][sub.2] complex is made to react, in dichloromethane, with the following ligands: 2-aminobenzonitrile (2abn), 4-aminobenzonitrile (4abn), 2-aminopyridine (2ampy) and 4-aminopyridine (4ampy), after addition of hexane, the following compounds are obtained: [Ru(p-cymene)Cl[sub.2](2abn)] (I), [Ru(p-cymene)Cl[sub.2](4abn)] (II), [Ru(p-cymene)Cl[sub.2](2ampy] (III) and [Ru(p-cymene)Cl[sub.2](μ-(4ampy)] (IV). All the compounds are characterized by elemental analysis of carbon, hydrogen and nitrogen, proton nuclear magnetic resonance, COSY [sup.1]H-[sup.1]H, high-resolution mass spectrometry (ESI), thermogravimetry and single-crystal X-ray diffraction (the crystal structure of III is reported and compared with the closely related literature of II). The cytotoxicity effects of complexes were described for cervical cancer HeLa cells via 3-(4.5-dimethylthiazol-2-yl)-2.5-diphenyltetrazolium bromide (MTT) assay. The results demonstrate a low in vitro anticancer potential of the complexes.
ISSN:1420-3049
1420-3049
DOI:10.3390/molecules27217264